Lotemax is a drug owned by Bausch And Lomb Inc. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 20, 2021. Details of Lotemax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5800807 | Ophthalmic compositions including glycerin and propylene glycol |
Jan, 2017
(7 years ago) |
Expired
|
FDA has granted several exclusivities to Lotemax. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lotemax, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lotemax.
Exclusivity Information
Lotemax holds 3 exclusivities. All of its exclusivities have expired in 2021. Details of Lotemax's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 28, 2015 |
| Pediatric Exclusivity(PED) | Oct 15, 2014 |
| M(M-229) | Jul 20, 2021 |
US patents provide insights into the exclusivity only within the United States, but Lotemax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lotemax's family patents as well as insights into ongoing legal events on those patents.
Lotemax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lotemax's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 20, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lotemax Generic API suppliers:
Loteprednol Etabonate is the generic name for the brand Lotemax. 5 different companies have already filed for the generic of Lotemax, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lotemax's generic
Alternative Brands for Lotemax
Lotemax which is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment., has several other brand drugs using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Alcon Labs Inc |
| ||
| Bausch And Lomb |
| ||
| Bausch And Lomb Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Lotemax's active ingredient. Check the complete list of approved generic manufacturers for Lotemax
About Lotemax
Lotemax is a drug owned by Bausch And Lomb Inc. It is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment. Lotemax uses Loteprednol Etabonate as an active ingredient. Lotemax was launched by Bausch And Lomb Inc in 2012.
Approval Date:
Lotemax was approved by FDA for market use on 28 September, 2012.
Active Ingredient:
Lotemax uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient
Treatment:
Lotemax is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment.
Dosage:
Lotemax is available in gel form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5% | GEL | Prescription | OPHTHALMIC |
Lotemax is a drug owned by Bausch And Lomb Inc. It is protected by 5 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 20, 2021. Details of Lotemax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5747061 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) |
Expired
|
|
US5540930 (Pediatric) | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Apr, 2014
(10 years ago) |
Expired
|
| US5747061 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(11 years ago) |
Expired
|
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(11 years ago) |
Expired
|
|
US4996335 (Pediatric) | Soft steroids having anti-inflammatory activity |
Sep, 2012
(12 years ago) |
Expired
|
FDA has granted several exclusivities to Lotemax. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lotemax, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lotemax.
Exclusivity Information
Lotemax holds 3 exclusivities. All of its exclusivities have expired in 2021. Details of Lotemax's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 28, 2015 |
| Pediatric Exclusivity(PED) | Oct 15, 2014 |
| M(M-229) | Jul 20, 2021 |
US patents provide insights into the exclusivity only within the United States, but Lotemax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lotemax's family patents as well as insights into ongoing legal events on those patents.
Lotemax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lotemax's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 20, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lotemax Generic API suppliers:
Loteprednol Etabonate is the generic name for the brand Lotemax. 5 different companies have already filed for the generic of Lotemax, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lotemax's generic
Alternative Brands for Lotemax
Lotemax which is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment., has several other brand drugs using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Alcon Labs Inc |
| ||
| Bausch And Lomb |
| ||
| Bausch And Lomb Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Lotemax's active ingredient. Check the complete list of approved generic manufacturers for Lotemax
About Lotemax
Lotemax is a drug owned by Bausch And Lomb Inc. It is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment. Lotemax uses Loteprednol Etabonate as an active ingredient. Lotemax was launched by Bausch And Lomb in 1998.
Approval Date:
Lotemax was approved by FDA for market use on 09 March, 1998.
Active Ingredient:
Lotemax uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient
Treatment:
Lotemax is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment.
Dosage:
Lotemax is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |
Lotemax is a drug owned by Pharmos Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 20, 2021. Details of Lotemax's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5540930 | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
Oct, 2013
(11 years ago) |
Expired
|
FDA has granted several exclusivities to Lotemax. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Lotemax, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Lotemax.
Exclusivity Information
Lotemax holds 3 exclusivities. All of its exclusivities have expired in 2021. Details of Lotemax's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Sep 28, 2015 |
| Pediatric Exclusivity(PED) | Oct 15, 2014 |
| M(M-229) | Jul 20, 2021 |
US patents provide insights into the exclusivity only within the United States, but Lotemax is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lotemax's family patents as well as insights into ongoing legal events on those patents.
Lotemax's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lotemax's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 20, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lotemax Generic API suppliers:
Loteprednol Etabonate is the generic name for the brand Lotemax. 5 different companies have already filed for the generic of Lotemax, with Sentiss having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lotemax's generic
Alternative Brands for Lotemax
Lotemax which is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment., has several other brand drugs using the same active ingredient (Loteprednol Etabonate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Alcon Labs Inc |
| ||
| Bausch And Lomb |
| ||
| Bausch And Lomb Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Loteprednol Etabonate, Lotemax's active ingredient. Check the complete list of approved generic manufacturers for Lotemax
About Lotemax
Lotemax is a drug owned by Pharmos Corp. It is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment. Lotemax uses Loteprednol Etabonate as an active ingredient. Lotemax was launched by Pharmos in 1998.
Approval Date:
Lotemax was approved by FDA for market use on 09 March, 1998.
Active Ingredient:
Lotemax uses Loteprednol Etabonate as the active ingredient. Check out other Drugs and Companies using Loteprednol Etabonate ingredient
Treatment:
Lotemax is used for treating steroid-responsive conditions in the eye, such as inflammation of the conjunctiva, cornea, and anterior segment.
Dosage:
Lotemax is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5% | SUSPENSION/DROPS | Discontinued | OPHTHALMIC |